Hematologic Malignancy
Prolymphocytic Leukemia
CI-CAN-00003763PLLExplore in graph →
Hematologic17 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003763PLLExplore in graph →
Clinical trials
95 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (18)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02662296 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02285244 | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation | withdrawn | Phase 2 | 0 | James BlachlyOTHER | 0 |
| Apr 5, 2017 |
| clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2017source: clinicaltrials